Published in Kidney Int on January 28, 2009
Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 4.46
C3 glomerulopathy: a new classification. Nat Rev Nephrol (2010) 3.17
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 1.70
Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol (2012) 1.58
Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis (2010) 1.57
Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int (2012) 1.45
Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol (2012) 1.43
Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol (2011) 1.38
Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol (2011) 1.31
Dense deposit disease. Mol Immunol (2011) 1.31
C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis (2013) 1.24
Recent insights into C3 glomerulopathy. Nephrol Dial Transplant (2013) 1.21
Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol (2013) 1.19
Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol (2010) 1.10
Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Mol Immunol (2009) 1.09
Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens (2013) 1.07
Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol (2013) 1.04
Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis. Am J Kidney Dis (2012) 1.03
Dense deposit disease and C3 glomerulopathy. Semin Nephrol (2013) 0.98
Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol (2013) 0.95
Blockade of alternative complement pathway in dense deposit disease. Case Rep Nephrol (2014) 0.92
C3 nephritic factor associated with C3 glomerulopathy in children. Pediatr Nephrol (2013) 0.91
Neutrophils: game changers in glomerulonephritis? Trends Mol Med (2010) 0.86
Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol (2013) 0.85
Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) (2010) 0.82
Tissue proteomics: a new investigative tool for renal biopsy analysis. Kidney Int (2009) 0.82
Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come. Clin Dev Immunol (2012) 0.81
Mass spectrometry-based proteomics in Chest Medicine, Gerontology, and Nephrology: subgroups omics for personalized medicine. Biomedicine (Taipei) (2014) 0.80
IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol (2014) 0.79
Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies. J Immunol (2013) 0.78
Proteomic analysis of formalin-fixed paraffin-embedded glomeruli suggests depletion of glomerular filtration barrier proteins in two-kidney, one-clip hypertensive rats. Nephrol Dial Transplant (2014) 0.78
Overlap of ultrastructural findings in C3 glomerulonephritis and dense deposit disease. Kidney Int (2015) 0.77
Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol (2013) 0.76
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World J Nephrol (2016) 0.76
Complement Factor H-Related 5-Hybrid Proteins Anchor Properdin and Activate Complement at Self-Surfaces. J Am Soc Nephrol (2015) 0.76
C3 Glomerulopathy. Pediatr Nephrol (2016) 0.76
A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol (2015) 0.76
Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience. Diagn Pathol (2015) 0.75
The incidence of possible causes of membranoproliferative glomerulonephritis: a single-center experience. Hippokratia (2016) 0.75
Current concepts in C3 glomerulopathy. Indian J Nephrol (2014) 0.75
Annexin A2 Enhances Complement Activation by Inhibiting Factor H. J Immunol (2016) 0.75
Serum C3 and Renal Outcome in Patients with Primary Focal Segmental Glomerulosclerosis. Sci Rep (2017) 0.75
Complement Factor H Binds to Human Serum Apolipoprotein E and Mediates Complement Regulation on High Density Lipoprotein Particles. J Biol Chem (2015) 0.75
Novel biomarkers in glomerular disease. Adv Chronic Kidney Dis (2014) 0.75
Changing the concepts of immune-mediated glomerular diseases through proteomics. Proteomics Clin Appl (2015) 0.75
American Society of Nephrology clinical pathological conference. Clin J Am Soc Nephrol (2014) 0.75
Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol (2016) 0.75
C3 glomerulopathy and current dilemmas. Clin Exp Nephrol (2016) 0.75
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem (2002) 35.30
A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem (2003) 29.58
Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics (2005) 10.60
Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet (2002) 4.22
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature (1977) 3.04
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet (2005) 2.92
Human apolipoprotein E. The complete amino acid sequence. J Biol Chem (1982) 2.64
Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int (2006) 2.64
Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry (1981) 2.61
The central role of the alternative complement pathway in human disease. J Immunol (2006) 2.53
Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans (2002) 2.23
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res (1982) 2.01
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest (2008) 1.94
Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. Proc Natl Acad Sci U S A (2006) 1.87
Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res (1990) 1.80
Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol (2001) 1.80
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol (2006) 1.63
Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol (2006) 1.58
Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement. Int Immunol (1990) 1.57
Structural insights into the central complement component C3. Mol Immunol (2006) 1.25
A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem (2001) 1.23
The membrane attack complex of complement induces caspase activation and apoptosis. Eur J Immunol (2002) 1.20
Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis (2001) 1.15
Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. Mol Immunol (2008) 1.12
Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. Mol Immunol (2005) 1.10
Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC). Clin Exp Immunol (2006) 1.06
MPGN II--genetically determined by defective complement regulation? Pediatr Nephrol (2006) 1.02
Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood (2002) 1.00
Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet (1995) 1.00
Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol (1996) 0.96
Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes (1998) 0.95
Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis. J Immunol Methods (1990) 0.91
Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care (1998) 0.90
Recombinant C345C and factor I modules of complement components C5 and C7 inhibit C7 incorporation into the complement membrane attack complex. J Immunol (2005) 0.89
European Lipoprotein Club: report of the 20th annual conference, Tutzing, 8-11 September 1997. Atherosclerosis (1998) 0.81
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A (2005) 13.44
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet (2005) 4.09
Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 3.85
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? Mutat Res (2008) 3.76
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int (2012) 3.05
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood (2009) 3.00
Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood (2009) 2.97
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet (2005) 2.63
MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene (2004) 2.62
Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int (2011) 2.61
Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood (2007) 2.46
Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat (2010) 2.44
Plasmablastic lymphoma and related disorders. Am J Clin Pathol (2011) 2.44
SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes. Proc Natl Acad Sci U S A (2004) 2.41
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood (2007) 2.31
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Factor H family proteins and human diseases. Trends Immunol (2008) 2.02
Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol (2013) 2.00
Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem (2003) 1.99
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood (2012) 1.96
An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet (2010) 1.95
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood (2008) 1.95
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol (2007) 1.94
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood (2005) 1.91
A forward genetics screen in mice identifies recessive deafness traits and reveals that pejvakin is essential for outer hair cell function. J Neurosci (2007) 1.90
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood (2010) 1.90
Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int (2012) 1.81
Prestin, a cochlear motor protein, is defective in non-syndromic hearing loss. Hum Mol Genet (2003) 1.80
Prevalence and evolutionary origins of the del(GJB6-D13S1830) mutation in the DFNB1 locus in hearing-impaired subjects: a multicenter study. Am J Hum Genet (2003) 1.79
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79
Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences. Hum Mutat (2004) 1.77
Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol (2007) 1.74
Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood (2003) 1.73
Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol (2012) 1.70
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood (2007) 1.70
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.70
Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA. J Proteome Res (2008) 1.67
Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat (2003) 1.67
Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67
Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood (2009) 1.67
Advancing genetic testing for deafness with genomic technology. J Med Genet (2013) 1.66
Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice. Am J Hum Genet (2008) 1.65
Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology (2008) 1.63
Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) (2006) 1.62
Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol (2005) 1.62
Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder. Mod Pathol (2008) 1.61
LfhA, a novel factor H-binding protein of Leptospira interrogans. Infect Immun (2006) 1.61
C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int (2008) 1.61
The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat (2007) 1.59
Transcriptional control of SLC26A4 is involved in Pendred syndrome and nonsyndromic enlargement of vestibular aqueduct (DFNB4). Am J Hum Genet (2007) 1.59
The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J Immunol (2007) 1.58
Glycerol-3-phosphate dehydrogenase 2 is a novel factor H-, factor H-like protein 1-, and plasminogen-binding surface protein of Candida albicans. J Infect Dis (2012) 1.58
Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis (2010) 1.57
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res (2009) 1.57
Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int (2011) 1.56
Frequency of Usher syndrome in two pediatric populations: Implications for genetic screening of deaf and hard of hearing children. Genet Med (2010) 1.56
Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid (2011) 1.55
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell (2012) 1.54
Plasma cell myeloma and related neoplasms. Am J Clin Pathol (2011) 1.52
Transcription factor SIX5 is mutated in patients with branchio-oto-renal syndrome. Am J Hum Genet (2007) 1.52
Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood (2014) 1.50
New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol (2002) 1.50
Audioprofile-directed screening identifies novel mutations in KCNQ4 causing hearing loss at the DFNA2 locus. Genet Med (2008) 1.49
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat (2006) 1.46
Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. Am J Clin Pathol (2013) 1.46
Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int (2012) 1.45
Simultaneous phenotyping and quantification of α-1-antitrypsin by liquid chromatography-tandem mass spectrometry. Clin Chem (2011) 1.45
Immune evasion of Borrelia burgdorferi: mapping of a complement-inhibitor factor H-binding site of BbCRASP-3, a novel member of the Erp protein family. Eur J Immunol (2003) 1.45
Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood (2002) 1.44
Chronic caloric restriction preserves mitochondrial function in senescence without increasing mitochondrial biogenesis. Cell Metab (2012) 1.44